On Friday, Stoke Therapeutics Inc (NASDAQ: STOK) was -1.47% drop from the session before settling in for the closing price of $9.50. A 52-week range for STOK has been $5.35 – $17.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 57.42% over the past five years. When this article was written, the company’s average yearly earnings per share was at 102.36%. With a float of $42.19 million, this company’s outstanding shares have now reached $54.60 million.
Let’s look at the performance matrix of the company that is accounted for 128 employees. In terms of profitability, gross margin is 15.2%, operating margin of 20.03%, and the pretax margin is 27.0%.
Stoke Therapeutics Inc (STOK) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Stoke Therapeutics Inc stocks. The insider ownership of Stoke Therapeutics Inc is 23.42%, while institutional ownership is 98.75%. The most recent insider transaction that took place on May 02 ’25, was worth 228,543. In this transaction CHIEF MEDICAL OFFICER of this company sold 22,790 shares at a rate of $10.03, taking the stock ownership to the 33,998 shares. Before that another transaction happened on May 01 ’25, when Company’s CHIEF MEDICAL OFFICER sold 3,841 for $10.00, making the entire transaction worth $38,410. This insider now owns 56,788 shares in total.
Stoke Therapeutics Inc (STOK) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.59 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 102.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.25% during the next five years compared to 1.74% growth over the previous five years of trading.
Stoke Therapeutics Inc (NASDAQ: STOK) Trading Performance Indicators
You can see what Stoke Therapeutics Inc (STOK) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.68. Likewise, its price to free cash flow for the trailing twelve months is 7.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.79, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -2.71 in one year’s time.
Technical Analysis of Stoke Therapeutics Inc (STOK)
Stoke Therapeutics Inc (NASDAQ: STOK) saw its 5-day average volume 0.66 million, a negative change from its year-to-date volume of 0.85 million. As of the previous 9 days, the stock’s Stochastic %D was 42.81%. Additionally, its Average True Range was 0.65.
During the past 100 days, Stoke Therapeutics Inc’s (STOK) raw stochastic average was set at 52.56%, which indicates a significant increase from 49.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.48% in the past 14 days, which was lower than the 78.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.39, while its 200-day Moving Average is $11.05. Nevertheless, the first resistance level for the watch stands at $9.57 in the near term. At $9.78, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.95. If the price goes on to break the first support level at $9.20, it is likely to go to the next support level at $9.03. The third support level lies at $8.82 if the price breaches the second support level.
Stoke Therapeutics Inc (NASDAQ: STOK) Key Stats
There are 54,597K outstanding shares of the company, which has a market capitalization of 511.03 million. As of now, sales total 36,560 K while income totals -88,980 K. Its latest quarter income was 158,570 K while its last quarter net income were 112,880 K.
